



HAL
open science

Analyses of human papillomavirus genotypes and viral loads in anogenital warts.

Siolian Liewang Rita Ball, David Winder, Katie Vaughan, Nashat Hanna, Jonathan Andre Michel Salomon Levy, Jane Sterling, Margaret Stanley, Peter Goon

► **To cite this version:**

Siolian Liewang Rita Ball, David Winder, Katie Vaughan, Nashat Hanna, Jonathan Andre Michel Salomon Levy, et al.. Analyses of human papillomavirus genotypes and viral loads in anogenital warts.. Journal of Medical Virology, 2011, 83 (8), pp.1345. 10.1002/jmv.22111 . hal-00652144

HAL Id: hal-00652144

<https://hal.science/hal-00652144>

Submitted on 15 Dec 2011

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Analyses of human papillomavirus genotypes and viral loads in anogenital warts.

Journal:	<i>Journal of Medical Virology</i>
Manuscript ID:	JMV-10-2180.R1
Wiley - Manuscript type:	Research Article
Date Submitted by the Author:	14-Feb-2011
Complete List of Authors:	Ball, Siolian; University of Cambridge, Division of Virology, Department of Pathology Winder, David; University of Cambridge, Division of Virology, Department of Pathology Vaughan, Katie; University of Cambridge, Division of Virology, Department of Pathology Hanna, Nashat; St Mary's Hospital, GU/HIV Medicine Levy, Jonathan; Université Paris Diderot. Sterling, Jane; University of Cambridge, Division of Virology, Department of Pathology Stanley, Margaret; University of Cambridge, Pathology Goon, Peter; University of Cambridge, Division of Virology, Department of Pathology
Keywords:	HPV, Genital warts, E6 DNA viral loads, E6 mRNA

SCHOLARONE™
Manuscripts

1
2
3
4 1
5 2 **Analyses of human papillomavirus genotypes and viral loads in anogenital warts.**
6
7 3
8

9 4 Siolian L. R. Ball^{1§}, David M. Winder¹, Katie Vaughan¹, Nashat Hanna², Jonathan Levy³, Jane C.
10
11 5 Sterling¹, Margaret A. Stanley¹, and Peter K. C. Goon¹.
12

13 6
14 7 ¹Dept of Pathology, University of Cambridge, Tennis Court Road, Cambridge CB2 1QP, United
15
16 8 Kingdom.
17

18 9 ²Dept of GU/HIV Medicine, St. Mary's Hospital, Praed Street, London W2 1NY, United Kingdom.
19

20 10 ³ Université Paris Diderot. ERAMUS scholar 2007.
21
22 11

23
24 12 Running title: HPV genotypes and viral loads in anogenital warts
25
26 13

27
28 14 [§]Corresponding author.

29
30 15 Mailing address: Division of Virology, Department of Pathology, University of Cambridge, Level
31
32 16 5 laboratories block, Addenbrooke's Hospital, Hills Road, Cambridge CB2 2QQ, United Kingdom.
33

34
35 17 Phone: +44-1223-763424. Fax: +44-1223-336926. Email: slrb2@cam.ac.uk
36
37 18

1
2
3 **1 Abstract**
4

5
6 2 *Condylomata acuminata* (genital warts) are the most common sexually transmitted viral
7
8 3 diseases. These lesions are caused by infection with mucosal human papillomaviruses (HPVs).
9
10 4 However there is limited information on HPV strain distribution involved in the molecular
11
12 5 pathogenesis of these lesions. To address this, the strain prevalence and the frequency of
13
14 6 multiple HPV infections were determined in wart tissue obtained from 31 patients attending a
15
16 7 wart clinic. These lesions were bisected and subjected to parallel DNA and mRNA extractions.
17
18 8 HPV-type prevalence and incidence of multiple infections were determined by the Roche Linear
19
20 9 Array assay. qPCR compared HPV6, 11 16 and 18 viral loads and RT-qPCR measured HPV 6 and
21
22 10 11 E6 genomic expression levels. 71% of these samples were infected with multiple HPVs. Only
23
24 11 1 sample was negative for HPV6 or 11 DNA. 48% of samples were positive for a high risk
25
26 12 (oncogenic) HPV. The results show that multiple infections in tissue are frequent and the
27
28 13 subsequent analysis of HPV6 and 11 E6 DNA viral loads suggested that other HPVs could be
29
30 14 causing lesions. Further analysis of HPV6/11 E6 mRNA levels showed that there was no
31
32 15 discernable relationship between HPV6 E6 DNA viral load and relative HPV 6 or 11 E6 mRNA
33
34 16 levels thereby questioning the relevance of viral load to lesion causality.
35
36
37
38
39
40
41
42
43
44

45 **17 Keywords:** HPV. Genital warts. E6 DNA viral loads. E6 mRNA.
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1 Introduction

2 Infection with Human papillomaviruses (HPVs) results in a major global disease burden. In
3 particular, HPVs infecting mucosal tissue cause very significant morbidity and mortality. Those
4 HPVs fall into 2 groups; the so-called 'low risk' strains that cause warts and the 'high risk'
5 (oncogenic) strains (particularly HPV 16 and 18) that are the cause of ano-genital and oro-
6 pharyngeal cancers [Winder et al., 2009; zur Hausen, 2002].

7 In the uterine cervix, multiple HPV infections are frequent [Schmitt et al., 2010]. Studies using
8 highly sensitive PCR based methods for HPV strain detection in ano-genital lesions indicate that
9 multiple types (including both high and low risk strains) can also be detected in *Condylomata*. In
10 such circumstances it is difficult to assign causality to a specific HPV strain, although over 90%
11 of these lesions are positive for HPVs 6 and 11 DNA [Brown et al., 1999]; [Aubin et al., 2008];
12 [Chan et al., 2009] and there has been a significant decline in incident wart disease since the
13 introduction of a quadrivalent L1 VLP vaccine (Gardasil™) raised against HPVs 6 and 11 together
14 with the oncogenic HPVs 16 and 18 in 2007 ([Fairley et al., 2009]; [Munoz et al., 2010]).

15 Clarification of the clinical relevance of the multiple HPV strains found in a wart sample from an
16 individual patient is important for understanding which HPV strain is causal and these data will
17 be informative in any cases of vaccine failure.

18 In this study, the HPV strain prevalence, the frequency of more than 1 type in *condylomata* and
19 the relevance of viral DNA load to early gene expression have been determined in order to in
20 assign lesion causality to HPV 6 or 11.

1 Materials and methods:**2 Clinical specimens and sample preparation.**

3 The study was approved by the local Research Ethics Committee and all patients provided
4 written informed consent for their tissues to be used for research. A total of 31
5 immunocompetent male and female patients attending the Department of GU/HIV Medicine,
6 St Mary's Hospital, London, UK, were recruited to the study. Genital wart samples were
7 obtained under local anaesthesia and the tissue bisected and snap frozen at the time of biopsy
8 for DNA and RNA extraction.

9 DNA extraction and HPV detection.

10 DNA was extracted with DNeasy™ blood and tissue kit (Qiagen, Crawley, UK), following the
11 manufacturer's instructions. HPV types in 62.5ng of sample DNA were identified using the
12 Roche Linear Array [Roche Diagnostics Ltd, Burgess Hill, UK][Woo et al., 2007].

13 Measurement of viral load

14 For Taqman™ qPCR, primers and probes were synthesised by Sigma Genosys, Gillingham, UK.
15 The primers and probes for human GAPDH [Coleman et al., 2008], HPV6, 11 and 18 E6/7 DNA
16 and β -globin (A) [Tucker et al., 2001] and for HPV16 E6/7 DNA, and human β -Globin (B) [de
17 Boer et al., 2007] have been previously described (Supplementary table S I). Amplification was
18 performed in 20 μ L using 10ng sample DNA and Hotstart Taq (Qiagen, Crawley, UK) with cycling
19 conditions as follows: initial Taq activation and template denaturation at 95°C for 15 min,
20 followed by 45 cycles of 15s at 95°C and 60s at 60°C, with acquisition of fluorescent signal at 60
21 seconds. Amplification was performed on a Rotor-Gene 3000 (Corbett Life Science, Qiagen,
22 Crawley, UK) and data analysed using the Rotor-Gene software, v6.1. All optimisation

1 experiments were performed in triplicate at least 3 times. It was determined that HPV18 and
2 HPV16 could be multiplexed with the additional GAPDH internal control but all other HPV
3 amplification reactions were performed separately in parallel with control reactions. Standard
4 curves were constructed using purified placental human DNA (Sigma-Aldrich, Gillingham, UK)
5 and purified plasmids containing the HPV of interest. Serial dilutions of 1 in 5 were constructed
6 (containing 100ng to 6.4pg human DNA and 10^5 to 6.4 copies of HPV per reaction). The
7 specificity of primers was determined under identical conditions with genomic HPV DNA (HPVs
8 1a, 2a, 3, 5, 6, 7, 8, 10, 11, 14, 16, 17, 18, 20, 31, 49, 50 or 57) at a concentration of 10^6
9 copies/ μ L. No significant non-specific reactions were observed. Viral load was expressed as
10 number of virus particles/cell assuming 1ng DNA \sim 150 cells [Leyva and Kelley, 1974]. Viral loads
11 < 0.01 copies/cell were deemed as insignificant.

12 **mRNA extraction, purification and cDNA synthesis.**

13 The second half of the bisected tissue sample was shredded at the time of excision and stored
14 at -80°C in RNAlater™ (Qiagen, Crawley, UK). The tissue was later resuspended in 200 μ L Trizol™
15 (Invitrogen, Paisley, UK) in a lysing matrix D tube (MP Biomedicals, Solon OH, USA) and
16 pulverised using a Bulletblender™ machine (Next Advance, Averill Park, NY, USA). RNA was
17 precipitated with isopropanol and resuspended in 50 μ L H₂O. After DNase I digestion, RNA was
18 recovered by column purification using PureLink™ RNA extraction kit (Invitrogen, Paisley, UK)
19 following manufacturer's instructions and a maximum of 5 μ g reverse transcribed using
20 Bioscript™ (Bioline, London, UK) after pre-incubation with random hexamer primers for 5min at
21 65°C . Reactions were performed as follows: 25°C for 10min, 42°C for 60min and 70°C for 15min.
22 No-RT controls were performed without the addition of enzyme. The resulting cDNAs were

1 diluted 1/10 with pure water before qRT-PCR analysis. RT-qPCR for HPV 6 and 11 E6/E7 was
2 performed as per qPCR with supplementary internal control primers (Supplementary table S II).
3 To enable multiplexing of mRNA internal controls, primer-pairs and probes were examined for
4 any potential primer-dimer pairs using
5 Autodimer™ (<http://www.cstl.nist.gov/div831/strbase/AutoDimerHomepage/AutoDimerProgramHomepage.htm>). RT-qPCR was performed for all HPVs as a single-plex assay using primers and
6 probe as listed in Table I.

8 **Measurement of viral RNA load**

9 Values of HPV mRNA copy number were determined by standard curves of genomic HPVs (as
10 described for DNA viral load). Relative cellular mRNA was determined by normalising CT values
11 of TBP (TATA-Box binding protein), YWHAZ (tyrosine 3-mono-oxygenase/tryptophan 5-mono-
12 oxygenase activation protein, zeta polypeptide) and HMBS (hydroxymethylbilane synthase)
13 triplex RT-qPCR to calibrator sample (sample 9). Primers and probes sequences were first
14 reported for TBP, YWHAZ and HMBS by [Radonic et al., 2005], [Ohl et al., 2006] and [Qian et al.,
15 2002] respectively.

16 **Data analysis and statistics**

17 The results from the Linear Array assay were compared to those obtained by qPCR. Unweighted
18 Kappa statistics were calculated by online software
19 (<http://www.graphpad.com/quickcalcs/kappa1.cfm>). Kappa values determined were ranked as
20 moderate, substantial or near perfect as described by Viera et al. [Viera and Garrett, 2005].

21

1 Results

2 DNA from all 31 genital wart samples was positive for β -globin and HPV using the Linear Array
3 assay. All the warts harboured at least one low-risk HPV (Table I), and, as expected, HPV 6 and
4 11 dominated and were present in 97%, with HPV 6 in 28 (90%) and HPV 11 in 10 lesions (32%).
5 In 9 lesions (29%), only HPV 6 was found. The frequency distribution of HPV strains in this
6 cohort of tissue is featured in figure 1.

7
8 22 of the warts (71%) were multiply infected (Table II). In 7 (22%), more than one low-risk HPV
9 was detected and in 15 (48%) a mixture of low- and high-risk types were found. 11 (35%) of the
10 samples contained HPV16 or 18 or both. Only one sample (sample 25) was not infected by HPV
11 6 or 11, but was infected by other low risk types 40, 84 and CP6108 in addition to the oncogenic
12 strains 16, 18, 33 and possibly 52. Other low and high risk strains detected are shown in Table II.

13
14 Viral load was assayed using 10ng of sample DNA as standardization experiments had shown
15 that the Taqman™ qPCR was unbalanced with 100ng or more DNA. A threshold level for copy
16 numbers of specific HPV E6/E7 DNA was assumed to be 10 copies/cell indicating the HPV in
17 question to have been replicated and so likely to be involved in the pathogenesis of the clinical
18 lesion [Doorbar, 2006]. In addition, the sample DNA was obtained from tissue containing both
19 epithelium and stroma, so the concentration of HPV in infected keratinocytes is likely to be
20 higher than the values obtained for the full biopsy.

21

1
2
3
4 1 Of the 28 warts positive for HPV 6 in Linear Array, 18 had a copy number of HPV 6 above
5
6 2 threshold value. 5 warts, in which there was co-detection of HPV 11, had a copy number of HPV
7
8 3 11 exceeding 10 copies/cell (Table II). 8/31 samples (26%) did not have viral loads above
9
10 4 threshold value of either HPV 6 or 11. In 3 of these, however, HPV 16 was detected at a level
11
12 5 above 10 copies/cell and was also positive in the Linear Array assay. In 4 of these 8 samples,
13
14 6 other low risk HPV strains, which were not tested by qPCR, had been detected in the Linear
15
16 7 Array assay and so potentially could have been causal in these lesions.
17
18
19
20

21 8
22
23 9 HPV 6 or 11 E6/E7 transcripts were detected and quantified in 23 samples. No tissue was
24
25 10 available for RNA extraction in 3 cases. In all samples where HPV mRNA was quantified at a
26
27 11 measurable level, the same HPV type had been found by the Linear Array assay. Only sample 8
28
29 12 had very low HPV6/11 DNA and mRNA levels, suggesting that one or more of the other low risk
30
31 13 HPVs present (55, 62, or 84) could have been causal in these lesions.
32
33
34
35
36
37
38

39 15 These data show that relatively small DNA viral loads are capable of producing high mRNA
40
41 16 levels as, for example, sample 1 had only 2 copies of HPV 6 per cell, but generated a relative
42
43 17 amount of 1163 copies of HPV 6 mRNA per reaction. The converse is also true, as the sample
44
45 18 with the largest HPV 6 DNA viral load (namely sample 15 with 870 copies/cell), did not yield the
46
47 19 largest E6/7 mRNA load. Five multiply infected samples (namely 1, 4, 8, 17 and 22) had low HPV
48
49 20 6 DNA viral loads (<10 copies/cell) suggesting that another HPV was responsible for the lesion.
50
51 21 However, analysis of relative mRNA levels revealed measurable HPV 6 E6 transcription in 4
52
53
54
55
56
57
58
59
60

1
2
3 1 samples (1, 4, 17 and 22) thus HPV 6 could still be causing these lesions. As HPV 6 E6 mRNA was
4
5
6 2 not measurable in sample 8, other low risk HPVs present (55, 62 or 84) may have been causal.
7
8
9 3
10
11 4 3 samples (3, 22 and 25) had copies of HPV 16 DNA viral loads above 10 copies/cell, raising the
12
13
14 5 possibility that these lesions could be caused by HPV 16. For sample 3, HPV 11 and 16 were
15
16 6 detected by the Linear Array assay, subsequent qPCR and RT-qPCR revealed HPV 11 E6 DNA and
17
18 7 E6 mRNA levels to be negligible whilst HPV 16 DNA was present at 177 copies/cell. These data
19
20
21 8 suggest HPV 16 is causing the lesion, although in the absence of HPV 16 mRNA measurement it
22
23
24 9 can only be speculated. In sample 22 (positive for HPV 6 and 16 DNA) HPV 6 mRNA was
25
26 10 abundant even though the HPV 6 DNA load was <10 copies/cell.
27
28
29 11
30
31 12 Sample 25, however was negative for HPV 6 and 11 on the Linear Array assay, but positive for
32
33
34 13 HPV 40, 84, CP, 16, 18, 33 and 52. The absence of measurement of the low risk HPVs 40, 84 and
35
36 14 CP6108 mRNAs meant that their contribution to the pathogenesis of this lesion could not be
37
38
39 15 discounted and it would be incautious to conclude that HPV 16 caused this lesion.
40
41
42 16
43
44 17 Inter-assay concordance values were derived using Cohen's κ algorithm (Table III) [Viera and
45
46 18 Garrett, 2005]. For all comparisons agreement was considered better than 'moderate' ($\kappa > 0.41$),
47
48
49 19 except between Linear Array results and relative mRNA levels for HPV 6 which was determined
50
51
52 20 to be 'fair'. These data suggest that the presence of HPV 6 L1 DNA as determined by the Linear
53
54 21 Array assay does not predict E6 genomic expression as measured by the RT-qPCR.
55
56
57
58
59
60

1 Discussion

2 This detailed DNA and RNA analysis of HPVs in genital warts attempted to identify not just the
3 HPV strains present in or on the lesion, but also to gather evidence of the HPV strains that could
4 be causing the lesions and producing infective virions. To our knowledge, there are no previous
5 published data for this type of analysis in *condylomata acuminata*. Most studies of HPV types in
6 genital warts have used surface swabs and PCR amplification with sequencing or hybridization
7 methods to identify multiple infections [Chan et al., 2009; Greer et al., 1995; Giuliano et al.,
8 2008; Sanclemente et al., 2007]. These sensitive methods can also detect HPV DNAs in the
9 anogenital region in asymptomatic individuals [Nielsen et al., 2009]. The potential risk from
10 analysis of surface samples is that the HPVs detected may reflect carriage but not necessarily
11 permissive viral growth. The analysis of lesion tissue should minimize false positive results due
12 to other non-lesion associated HPVs within this body area.

13
14 It was no surprise to find HPV 6 was the most frequently detected in these lesions with HPV 11
15 as the second most prevalent type. This is in accordance with previous data for other studies
16 using the Linear Array assay in genital wart swabs [Aubin et al., 2008; Chan et al., 2009] and
17 tissue [Potocnik et al., 2007]. The finding of high risk HPVs in 35% of samples in this
18 immunocompetent group is in keeping with other reports of high risk types detected in 14-44%
19 of non-immunosuppressed individuals [Brown et al., 1999; Potocnik et al., 2007] but below that
20 found in patient groups with a higher HIV positive prevalence where high risk HPVs may be
21 present in 47-100% of genital warts [Brown et al., 1999; Müller et al., 2010; Schlecht et al.,
22 2010].

1
2
3 1
4
5
6 2 This data from immunocompetent patients show that 71% excised wart samples contained dual
7
8 3 or multiple HPV types, agreeing with previous estimates [Brown et al., 1999; Aubin et al., 2008,
9
10 4 Chan et al., 2009]. The Linear Array assay has the advantage of simultaneously detecting the
11
12 5 presence of 37 genital HPV types [Woo et al., 2007] and is considered the most sensitive test of
13
14 6 its kind [van Ham et al., 2005; van Hamont et al., 2006]. The advantage of qPCR is the ability to
15
16 7 estimate viral load, allowing comparison of specific HPV subtypes in multiply infected samples.
17
18 8 The inter-assay agreement levels between the Linear Array assay and qPCR was good and
19
20 9 validated the use of either assay for screening.
21
22
23
24
25
26 10

27
28 11 The identification of HPV strains other than 6 or 11 causing genital warts will be important for
29
30 12 future vaccination strategies, although the reduction of anogenital warts since the introduction
31
32 13 of the quadrivalent vaccine, Gardasil™ [Fairley et al., 2009; Munoz et al., 2010], supports
33
34 14 confirmation presented here of the role of HPV 6 or 11 in causing lesions, even in multiply
35
36 15 infected samples or when their DNA loads are low. One concern is that if lesions caused by HPV
37
38 16 6 and 11 are eradicated, other HPVs may become more prevalent and therefore more
39
40 17 important for identification, and subsequent confirmation of which HPV is causal. Confirmation
41
42 18 and quantitation of other HPV mRNAs would be desirable, but as yet there is no equivalent of
43
44 19 the Linear Array assay for HPV mRNA analysis and this study was limited to the primer and
45
46 20 probe sets in the laboratory. The PreTect™ HPV Proofer and Aptima™ systems are designed for
47
48 21 the detection of high-risk HPV mRNA only [Halfon et al., 2010; Molden et al., 2007; Keegan et
49
50 22 al., 2009] and so would be unsuitable for *Condylomata*.

1
2
3
4 1
5
6 2 The choice of E6/E7 transcript in this study was based on their known roles in the viral
7
8 3 infectious cycle [Doorbar, 2006]. Studies investigating the DNA and mRNA loads of oncogenic
9
10 4 HPVs in cervical intraepithelial neoplasia (CIN) have concluded that E6 RNA load is a better
11
12 5 predictor of lesion severity [de Boer et al., 2007; Cattani et al., 2009; Ho et al., 2010] and
13
14 6 progression levels [de Boer et al., 2007], and although malignant progression was not likely in
15
16 7 these lesions, E6 RNA abundance probably reflects viral contribution to lesion pathogenesis. As
17
18 8 demonstrated in this report, DNA loads of low-risk subtypes, HPV 6 and 11, do not correlate
19
20 9 with their respective mRNA E6 transcript levels and is similar to that observed in HPV 16-
21
22 10 associated CIN [de Boer et al., 2007; Cattani et al., 2009]. Therefore, viral genome copy number
23
24 11 does not directly reflect viral activity.
25
26
27
28
29
30
31
32

33 13 HPV16 is not thought to produce *Condyloma*-like lesions [zur Hausen, 2002] although one
34
35 14 reported case [Chrisofos et al., 2004] based on DNA analysis alone, suggests that it may. The
36
37 15 DNA analysis shows 3 samples in which HPV 16 DNA was detected by the Linear Array assay and
38
39 16 also at a significant level by qPCR, suggesting that this oncogenic type is amplified within these
40
41 17 lesions, but this can only be confirmed by quantitation of the mRNA which was not performed
42
43 18 in this study.
44
45
46
47
48
49
50

51 20 These data provide evidence for multiple subtype infection as a common event in the natural
52
53 21 history of *Condylomata acuminata*, but with significant replicative activity of usually HPV 6 or
54
55 22 11. DNA viral loads alone are insufficient to truly determine which HPV is causal, and mRNA
56
57
58
59
60

1
2
3 1 analysis is required to discount the contribution of HPV 6 and/or 11 when DNA loads are low. In
4
5
6 2 order to confirm these findings, a prospective study including larger numbers of patients, rather
7
8
9 3 than an unselected collection of warts should be performed. It is likely that analysis of HPV
10
11 4 mRNA would provide data informative for HPV vaccines and will be especially useful in the
12
13 5 event of vaccine failure.
14
15
16 6

17 18 7 Disclosure of Conflicts of Interest

19
20
21 8 This work was supported by grants from the British Skin Foundation and Cancer Research UK to
22
23 9 PKCG. PKCG and MAS act as consultants to Sanofi Pasteur-MSD, Lyon, France and are in receipt
24
25
26 10 of an unrestricted educational grant. MAS also acts as consultant to Merck Research
27
28
29 11 Laboratories, Westpoint, USA, and GSK Biologicals, Rixensart, Belgium.
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 **References**
4

- 5
6 2 Aubin F, Pr  tet JL, Jacquard AC, Saunier M, Carcopino X, Jaroud F, Pradat P, Soubeyrand B, Leocmach
7 3 Y, Mougin C, Riethmuller D. 2008. Human papillomavirus genotype distribution in external
8 4 acuminata condylomata: A large French national study (EDiTH IV). *Clin Infect Dis* 47:610-615.
9 5 Brown DR, Schroeder JM, Bryan JT, Stoler MH, Fife KH. 1999. Detection of multiple human
10 6 papillomavirus types in condylomata acuminata lesions from otherwise healthy and
11 7 immunosuppressed patients. *J Clin Microbiol* 37:3316-3322.
12 8 Cattani P, Siddu A, D'Onghia S, Marchetti S, Santangelo R, Vellone VG, Zannoni GF, Fadda G. 2009.
13 9 RNA (E6 and E7) assays versus DNA (E6 and E7) assays for risk evaluation for women infected
14 10 with Human papillomavirus. *J Clin Microbiol* 47:2136-2141.
15 11 Chan PKS, Luk ACS, Luk TNM, Lee K-F, Cheung JLK, Ho K-M, Lo K-K. 2009. Distribution of human
16 12 papillomavirus types in anogenital warts of men. *J Clin Virol* 44:111-114.
17 13 Chrisofos M, Skolarikos A, Lazaris A, Bogris S, Deliveliotis C. 2004. HPV 16/18-associated condyloma
18 14 acuminatum of the urinary bladder: first international report and review of literature. *Int J*
19 15 *STD AIDS* 15:836-838.
20 16 Coleman HM, Connor V, Cheng ZSC, Grey F, Preston CM, Efstathiou S. 2008. Histone modifications
21 17 associated with herpes simplex virus type 1 genomes during quiescence and following ICPO-
22 18 mediated de-repression. *J Gen Virol* 89:68-77.
23 19 de Boer MA, Jordanova ES, Kenter GG, Peters AA, Corver WE, Trimbos JB, Fleuren GJ. 2007. High
24 20 Human papillomavirus oncogene mRNA expression and not viral DNA load is associated with
25 21 poor prognosis in cervical cancer patients. *Clin Cancer Res* 13:132-138.
26 22 Doorbar J. 2006. Molecular biology of human papillomavirus infection and cervical cancer. *Clin Sci*
27 23 110:525-541.
28 24 Fairley CK, Hocking JS, Gurrin LC, Chen MY, Donovan B, Bradshaw C. 2009. Rapid decline in
29 25 presentations for genital warts after the implementation of a national quadrivalent human
30 26 papillomavirus vaccination program for young women. *Sex Transm Infect:sti*.2009.037788.
31 27 Giuliano AR, Tortolero-Luna G, Ferrer E, Burchell AN, de Sanjose S, Kjaer SK, Mu  oz N, Schiffman M,
32 28 Bosch FX. 2008. Epidemiology of human papillomavirus infection in men, cancers other than
33 29 cervical and benign conditions. *Vaccine* 26 (Suppl 10):K17-K28.
34 30 Greer CE, Wheeler CM, Ladner MB, Beutner K, Coyne MY, Liang H, Langenberg A, Yen TS, Ralston R.
35 31 1995. Human papillomavirus (HPV) type distribution and serological response to HPV type 6
36 32 virus-like particles in patients with genital warts. *J Clin Microbiol* 33:2058-2063.
37 33 Halfon P, Benmoura D, Agostini A, Khiri H, Martineau A, Penaranda G, Blanc B. 2010. Relevance of
38 34 HPV mRNA detection in a population of ASCUS plus women using the NucliSENS EasyQ[ ] HPV
39 35 assay. *J Clin Virol* 47:177-181.
40 36 Ho CM, Lee BH, Chang SF, Chien TY, Huang SH, Yan CC, Cheng WF. 2010. Type-specific human
41 37 papillomavirus oncogene messenger RNA levels correlate with the severity of cervical
42 38 neoplasia. *Int J Cancer* 127:622-632.
43 39 Keegan H, Mc Inerney J, Pilkington L, Gr  nn P, Silva I, Karlsen F, Bolger N, Logan C, Furuberg L,
44 40 O'Leary J, Martin C. 2009. Comparison of HPV detection technologies: Hybrid capture 2,
45 41 PreTect(TM) HPV-Proofer and analysis of HPV DNA viral load in HPV16, HPV18 and HPV33
46 42 E6/E7 mRNA positive specimens. *J Virol Methods* 155:61-66.
47 43 Leyva A, Kelley WN. 1974. Measurement of DNA in cultured human cells. *Anal Biochem* 62:173-179.
48 44 Molden T, Kraus I, Skomedal H, Nordstr  m T, Karlsen F. 2007. PreTect(TM) HPV-Proofer: Real-time
49 45 detection and typing of E6/E7 mRNA from carcinogenic human papillomaviruses. *J Virol*
50 46 *Methods* 142:204-212.
51 47 M  ller EE, Chirwa TF, Lewis DA. 2010. Human papillomavirus (HPV) infection in heterosexual South
52 48 African men attending sexual health services: associations between HPV and HIV serostatus.
53 49 *Sex Transm Infect* 86:175-180.
54 60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51

- Munoz N, Kjaer SK, Sigurdsson K, Iversen O-E, Hernandez-Avila M, Wheeler CM, Perez G, Brown DR, Koutsky LA, Tay EH, Garcia PJ, Ault KA, Garland SM, Leodolter S, Olsson S-E, Tang GWK, Ferris DG, Paavonen J, Steben M, Bosch FX, Dillner J, Huh WK, Joura EA, Kurman RJ, Majewski S, Myers ER, Villa LL, Taddeo FJ, Roberts C, Tadesse A, Bryan JT, Lupinacci LC, Giacoletti KED, Sing S, James MK, Hesley TM, Barr E, Haupt RM. 2010. Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women. *J Natl Cancer Inst* 102:325-339.
- Nielson CM, Harris RB, Flores R, Abrahamsen M, Papenfuss MR, Dunne EF, Markowitz LE, Giuliano AR. 2009. Multiple-type Human papillomavirus infection in male anogenital sites: Prevalence and associated factors. *Cancer Epidemiol Biomarkers Prev* 18:1077-1083.
- Ohl F, Jung M, Radonic A, Sachs M, Loening SA, Jung K. 2006. Identification and validation of suitable endogenous reference genes for gene expression studies of human bladder cancer. *J Urol* 175:1915 - 1920.
- Potocnik M, Kocjan BJ, Seme K, Poljak M. 2007. Distribution of human papillomavirus (HPV) genotypes in genital warts from males in Slovenia. *Acta Dermatovenerol Alp Panonica Adriat* 16:91-98.
- Qian Z, Fernald AA, Godley LA, Larson RA, Le Beau MM. 2002. Expression profiling of CD34+ hematopoietic stem/progenitor cells reveals distinct subtypes of therapy-related acute myeloid leukemia. *Proc Natl Acad Sci USA* 99:14925-14930.
- Radonic A, Thulke S, Bae H-G, Muller M, Siegert W, Nitsche A. 2005. Reference gene selection for quantitative real-time PCR analysis in virus infected cells: SARS corona virus, Yellow fever virus, Human Herpesvirus-6, Camelpox virus and Cytomegalovirus infections. *Virology Journal* 2:7.
- Sanclimente G, Herrera S, Tyring SK, Rady PL, Zuleta JJ, Correa LA, He Q, Wolff JC. 2007. Human papillomavirus (HPV) viral load and HPV type in the clinical outcome of HIV-positive patients treated with imiquimod for anogenital warts and anal intraepithelial neoplasia. *J Eur Acad Dermatol* 21:1054-1060.
- Schlecht HP, Fugelso Dana K, Murphy Ryan K, Wagner Katiri T, Doweiko John P, Proper J, Dezube Bruce J, Panther Lori A. 2010. Frequency of occult high grade squamous intraepithelial neoplasia and invasive cancer within anal condylomata in men who have sex with men. *Clin Infect Dis* 51:107-110.
- Schmitt M, Dondog B, Waterboer T, Pawlita M, Tommasino M, Gheit T. 2010. Abundance of Multiple High-Risk Human Papillomavirus (HPV) Infections found in cervical cells analyzed by use of an ultrasensitive HPV genotyping assay. *J Clin Microbiol* 48:143-149.
- Tucker RA, Unger ER, Holloway BP, Swan DC. 2001. Real-time PCR-based fluorescent assay for quantitation of human papillomavirus types 6, 11, 16, and 18. *Mol Diagn* 6:39-47.
- van Ham MAPC, Bakkens JMJE, Harbers GK, Quint WGV, Massuger LFAG, Melchers WJG. 2005. Comparison of two commercial assays for detection of human papillomavirus (HPV) in cervical scrape specimens: validation of the Roche AMPLICOR HPV Test as a means to screen for HPV genotypes associated with a higher risk of cervical disorders. *J Clin Microbiol* 43:2662-2667.
- van Hamont D, van Ham MAPC, Bakkens JMJE, Massuger LFAG, Melchers WJG. 2006. Evaluation of the SPF10-INNO LiPA human papillomavirus (HPV) genotyping test and the Roche Linear Array HPV genotyping test. *J Clin Microbiol* 44:3122-3129.
- Viera AJ, Garrett JM. 2005. Understanding interobserver agreement: The Kappa statistic. *Fam Med* 37:360-363.
- Winder DM, Ball SLR, Vaughan K, Hanna N, Woo YL, Fränzer J-T, Sterling JC, Stanley MA, Sudhoff H, Goon PKC. 2009. Sensitive HPV detection in oropharyngeal cancers. *BMC Cancer* 9:440.
- Woo YL, Damay I, Stanley M, Crawford R, Sterling J. 2007. The use of HPV Linear Array Assay for multiple HPV typing on archival frozen tissue and DNA specimens. *J Virol Methods* 142:226-230.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1 zur Hausen H. 2002. Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev
2 Cancer 2:342-350.
3
4

For Peer Review

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1 **Figures**

2
3
4

1 **Supplementary table S I**

Target	Accession Number	Forward Primer	Reverse Primer	Probe	Optimised primer concentration (nM)
HPV6	AF092932	GTTCCATAAAGCTAAATTG TACGTGGAA	TGTGAATCTTGTCCGTC CACTT	[6FAM]- ACAATATCCTTTAGGGTAAC ATGTCTTCCATGCATG - [TAMRA]	75
HPV11	M14119	GCTTCATAAACTAAATA ACCAGTGGAA	TGCGTCTTGTGTCCA CCTT	[6FAM]- CTATATCCTTTAGGGTAACA AGTCTTCCATGCATGTTG- [TAMRA]	75
HPV16	K02718	CCGGACAGAGCCATTAC AAT	ACGTGTGCTTTGTACG CAC	[6FAM]- TGTTGCAAGTGTGACTCTAC GCTTCGGT-[BHQ1]	100
HPV18	NC_001357	CAACCCGAGCACGACAGG AA	CTCGTCGGGCTGGTAA ATGTT	[6FAM]- AATATTAAGTATGCATGGA CCTAAGGCAACATTGCAA- [BHQ1]	100
β -globin (A)	NG_000007	CAGGTACGGCTGCATCA CTTAGA	CATGGTGTCTGTTGA GGTTGCTA	[TET]- GCCCTGACTTTTATGCCAG CCCTG-[BHQ1]	500
β -globin (B)	NG_000007	GACAGGTACGGCTGCATCA TCA	TAGATGGCTCTGCCCT GACT	[TET]- CTAGGGTTGGCCAATCTAC TCCCAG-[BHQ1]	100
GAPDH	NM_002046	CGGCTACTAGCGGTTTTA CG	AAGAAGATGCGGCTG ACTGT	[Cy5]- CACGTAGCTCAGGCCCTCAA GACCT-[BHQ3]	300

5
6
7
8
9
10
11
12
13
14

Supplementary table I.

8 **Primers and probe sets used in qPCR assay of viral load.**

9 Primer/probe sets used for the detection of HPV and Human DNA in DNA samples
10 generated from wart tissue. Sequences are represented 5'-3' and the 5' fluorescent labels
11 indicated (6FAM - 6-carboxyfluorescein, TET - tetrachloro-6-carboxyfluorescein or Cy5 -
12 cyanine). Tetramethylrhodamine (TAMRA), Black Hole Quencher 1 (BHQ1) or Black Hole
13 Quencher 3 (BHQ3) was incorporated at the 3' end of each probe.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3

1 **Supplementary table S II**

Target	Accession Number	Forward Primer	Reverse Primer	Probe	[Primer] (nM)
TBP (233)	NM_003194	TTCGGAGAGTTC TGGGATTGTA	TGGACTGTTCTTC ACTCTTGGC	[6FAM]- CCGTGGTTCGTGGCTCTCTT ATCCTCAT- [BHQ1]	60
YWHAZ (196)	NM_145690	AAGTTCTTGATCC CCAATGCTT	GTCTGATAGGAT GTGTTGGTTGC	[TET]- TATGCTTGTTGTGACTGATC GACAATCCCT-[BHQ2]	80
HMBS (82)	NM_000190	ACTTTCCAAGCG GAGCCAT	CGAATCACTCTC ATCTTTGG	[Cy5]- CGGCTGCAACGGCGGAAG AAAAC-[BHQ3]	100

4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

4
5
6
7
8
9
10
11
12
13

4
5
6
7
8
9
10
11
12
13

Supplementary table S II.

mRNA housekeeping/internal control primer sequences and probe sets.

Primer/probe sets used for the detection of internal control housekeeping transcripts in cDNA samples. Sequences are represented 5'-3' and the 5' fluorescent labels indicated (6FAM - 6-carboxyfluorescein, TET – tetrachloro-6-carboxyfluorescein or Cy5 - cyanine). Tetramethylrhodamine (TAMRA), Black Hole Quencher 1 (BHQ1) or Black Hole Quencher 2 (BHQ2) was incorporated at the 3' end of each probe. Amplicon size is in brackets (number of base pairs).

1
2
3 **Table I**4
5 26
7 3

	Number of samples (%)
HPV positive	31 (100)
HPV6+	28 (90)
HPV6 plus other	21 (68)
HPV11 +	10 (32)
High Risk HPV+	15 (48)
Single Infections	9 (29)
Dual infections	11 (35)
Triple Infections	3 (10)
More than 3 HPVs present	8 (26)

19
20 421
22 5

23 6 Table I.

24 7 **Summary of Linear Array results.**25
26 8
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table II

Sample Number	Linear Array Result		Taqman™ qPCR results.				Relative HPV RNA load	
	(HPV type present)		(copies/cell)				(copies/reaction)	
	Low risk	High risk	HPV6	HPV11	HPV16	HPV18	HPV6	HPV11
1	6, 40	18	2	-	-	-	1163	-
2	6		13	-	-	-	354	-
3	11	16	-	-	177	-	-	-
4	6, 42		3	-	-	-	53	-
5	6		27	-	-	-	NA	NA
6	6, 11		-	51	-	-	-	71
7	6, 42, 54, CP	31, 39	198	-	-	-	18	-
8	6, 55, 62, 84	45	-	-	-	-	-	-
9	6, 11		46	-	-	-	4764	-
10	6, 11		-	123	-	-	-	6905
11	6	18	14	-	-	-	5630	-
12	6		351	-	-	-	20	-
13	6, 11, CP	16	-	190	-	-	-	21604
14	6		35	-	-	-	NA	NA
15	6	18, 45, 51, 59	870	-	-	-	4036	-
16	6		59	-	-	-	21735	-
17	6, 67	52? 58	8	-	-	-	243	-
18	6	18	12	-	-	-	2712	-
19	6, 11		456	-	-	-	51	-
20	6, 11, 69, 84	16	-	251	-	-	6	67
21	6		26	-	-	-	493	-
22	6	16	3	-	16	-	141	-
23	6		147	-	-	-	616	-
24	6		12	-	-	-	959	-
25	40, 84, CP	16, 18, 33, 52?	-	-	11	-	-	-
26	6, 11		85	-	-	-	3715	13
27	6	45	203	-	-	-	-	-
28	6	18, 59	61	-	-	-	3289	-
29	6, 11, 84		19	558	-	-	676	7662
30	11, 42, 64	18	-	284	-	-	NA	NA
31	6		-	-	-	-	-	-

Table II.

Linear Array Results vs qPCR Viral Load and Relative RNA load.

Samples were assayed for the appearance and DNA and RNA viral load of HPV as described in the methods section. (-) denotes not significantly positive during assay (less than 1 copy/cell or 5 copies/reaction total RNA). CP represents CP6108. 52? denotes positivity at the 52/33/35/58 band on the Linear Array, but also for individual 33 and 58 markers, but where the presence of 52 cannot be discounted as described in the manufacturer's instructions. NA denotes no tissue available for RNA analysis.

1
2
3 **Table III.**4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Comparison between positive results	HPV6	HPV11
Linear Array vs qPCR DNA	0.415	0.67
Linear Array vs RT-qPCR RNA	0.323	0.731
qPCR DNA vs RT-qPCR RNA	0.825	0.887

6 **Table III.**7 **Interassay concordance data.**8 Cohen's κ coefficients were derived as described in the methods section.

Figure 1




Fig. 1.

Distribution of HPV types in wart tissue as determined by Linear Array.

All occurrences of HPV were scored, regardless of being single or multiple infections.

For Peer Review